PanXome ("pan-exome”) opens new regions of drug exploration using proprietary algorithms that greatly expand, accelerate and de-risk drug discovery. Our software provides reliable predictions of disease-associated protein targets, small molecule binding and side effects. The scale and accuracy of the PanXome platform is unprecedented in the industry. Traditionally, drug companies have relied on the process of screening thousands of compounds and extensive in vitro testing against a target to establish binding properties, efficacy and side-effects. Competing computational methods only cover about 25% of the human proteome whereas PanXome covers 86% of the human proteome. ' The core technology was developed by the company’s CSO, Dr. Jeff Skolnick, over the last 10 years. PanXome owns an exclusive, worldwide license from Georgia Tech for all fields of use to the algorithms and software that Dr. Skolnick has developed. The company is privately funded and is headquartered in Atlanta, GA, USA.